Association between HLA-B*1502 allele and carbamazepine-induced severe cutaneous adverse reactions in Han people of southern China mainland

Zaccara, 2007, Idiosyncratic adverse reactions to antiepileptic drugs, Epilepsia, 48, 1223, 10.1111/j.1528-1167.2007.01041.x Ferrell, 2008, Carbamazepine HLA-B*1502 and risk of Stevens–Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations, Pharmacogenomics, 9, 1543, 10.2217/14622416.9.10.1543 Roujeau, 1994, Severe adverse cutaneous reactions to drugs, N Engl J Med, 331, 1272, 10.1056/NEJM199411103311906 Bunce, 1995, Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4 DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP), Tissue Antigens, 46, 355, 10.1111/j.1399-0039.1995.tb03127.x Jewell, 1986, On the bias of commonly used measures of association for 2×2 tables, Biometrics, 42, 351, 10.2307/2531055 Li, 2006, HLA-B gene polymorphism detected by high-resolution sequence-based typing in Guangdong Han populations, Zhonghua Yi Xue Yi Chuan Xue Za Zhi, 23, 50 Geer, 1998, 327 Chung, 2004, Medical genetics: a marker for Stevens–Johnson syndrome, Nature, 428, 486, 10.1038/428486a Man, 2007, Association between HLA-B*1502 allele and antiepileptic druginduced cutaneous reactions in Han Chinese, Epilepsia, 48, 1015, 10.1111/j.1528-1167.2007.01022.x Locharernkul, 2008, Carbamazepine and phenytoin induced Stevens–Johnson syndrome is associated with HLA-B*1502 allele in Thai population, Epilepsia, 49, 2087, 10.1111/j.1528-1167.2008.01719.x Kaniwa, 2008, HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens–Johnson syndrome and toxic epidermal necrolysis, Pharmacogenomics, 9, 1617, 10.2217/14622416.9.11.1617 Tanaka, 1996, Report of the Japanese central bone marrow data center, Clin Transpl, 139 Alfirevic, 2006, HLA-B locus in Caucasian patients with carbamazepine hypersensitivity, Pharmacogenomics, 7, 813, 10.2217/14622416.7.6.813 Hung, 2006, Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions, Pharmacogenet Genomics, 16, 297, 10.1097/01.fpc.0000199500.46842.4a